A n effective malaria vaccine would be instrumental in eliminating the disease, which causes over 200 million cases and nearly half a million deaths annually 1 . One unique approach is a transmission-blocking vaccine (TBV). TBVs cause immunized hosts to transfer induced antibodies to mosquitos during a blood meal, blocking parasite development in the mosquito gut. A vaccine that reduces parasite transmission is part of the World Health Organization Malaria Vaccine Technology Roadmap, but has not yet been evaluated in large-scale trials, due in part to challenges in developing a TBV that produces high and sustained levels of transmission-blocking antibodies 2, 3 . Plasmodium falciparum Pfs25 is an intensively studied TBV antigen candidate [4] [5] [6] . The 25 kDa protein contains 11 disulfide bonds, so the production of properly folded Pfs25 is of interest [7] [8] [9] [10] . Clinical trials with Pfs25 or Plasmodium vivax Pvs25 have failed to produce satisfactory levels of antibodies using alum as a vaccine adjuvant, and the use of Montanide ISA 51 as an adjuvant resulted in unexpected local reactogenicity 11, 12 . The limited immunogenicity of Pfs25 may be related to its compact structure and putative haptenlike behaviour 13 . Antigen engineering has been pursued to improve the induction of antibodies against Pfs25. This includes: conjugation to protein toxins (from Pseudomonas 14 , cholera 15, 16 or tetanus 13 ); conjugation to nanoparticles (such as gold 17 or polymer 18 ); engineering Pfs25 in virus-like particles 19 ; and the use of viral vectors 20 . Emerging approaches include the use of recombinant protein tags for downstream Pfs25 multimerization 21 or attachment to virus-like particles 22 . While these strategies hold potential, genetically engineered constructs or conjugation strategies are time-and resource-consuming, can induce heterogeneous antigen populations, can mask important epitopes, risk incorrect folding and can impede target antigen characterization within the resulting constructs.
Liposomes containing cobalt porphyrin-phospholipid (CoPoP) can be stably functionalized by simple mixing with proteins bearing a polyhistidine-tag (his-tag)-a small 6-10 stretch of histidine residues used in recombinant protein purification 23 . A carboxy (C)-terminal his-tagged and glycosylation-free Pfs25 was recently produced in a baculovirus system 10 . The 11 disulfide bonds of this protein match the predicted structure of the analogous P. vivax Pvs25 24 . Here, we make use of this well-characterized his-tagged antigen for spontaneous nanoliposome antigen particleization (SNAP). Spontaneous particleization (that is, binding of soluble, recombinant antigens to nanoliposomes so that they decorate the surface of the colloidal particles) occurs when the antigens stably bind to membranes via insertion and coordination of the his-tag into bilayers containing CoPoP.
SNAP
We formed liposomes with two active lipids-a synthetic monophosphoryl lipid A (phosphorylated hexaacyl disaccharide (PHAD); a toll-like receptor 4 agonist) and CoPoP, which is biologically inert but confers spontaneous his-tag antigen particelization. Two passive lipids completed the formulation-1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol. Liposomes were produced with a mass ratio of 4:2:1:1 of DPPC:cholesterol:CoPoP:PHAD unless otherwise indicated. Native polyacrylamide gel electrophoresis showed that, with simple mixing, Pfs25 bound to liposomes containing CoPoP, but not to liposomes containing porphyrin-phospholipid (PoP), which are identical but lack cobalt (Fig. 1a) . Liposomes containing a nickel-chelated 
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NAture NANotecHNology headgroup lipid (Ni-NTA) did not stably bind Pfs25. With CoPoP, the his-tag buries itself within the hydrophobic cobalt porphyrin bilayer and coordinates with the metal, resulting in attachment that is stable in biological media. Liposomal Ni-NTA approaches for binding his-tagged ligands are unstable in biological media 23, 25, 26 . Liposomal Co-NTA has been explored for immunization, but the approach was found to be inferior to covalent linkage 27 . We previously found that Co-NTA cannot stably bind his-tagged peptides 23 . When varying amounts of CoPoP/PHAD liposomes were incubated with Pfs25, a 4:1 mass ratio of PHAD to protein was sufficient for binding (Fig. 1b) . This is equivalent to a CoPoP:Pfs25 mass ratio of 4:1 and a lipid:Pfs25 mass ratio of 32:1. Pfs25 did not bind PoP/ PHAD liposomes. A similar trend was observed with a microcentrifugal filtration binding assay (Fig. 1c,d ). Lysozyme-a protein without a his-tag-did not bind to CoPoP liposomes (Fig. 1d) . Approximately 80% Pfs25 binding was achieved at room temperature in 3 h (Fig. 1e) . These particleization conditions (4:1 mass ratio of CoPoP (320 µ g ml −1 ) to Pfs25 (80 µ g ml −1 ), combined in equal volume and incubated without shaking at room temperature for 3 h) were fixed for all studies, and the desired dosing was achieved by subsequent dilution in buffered saline.
His-tagged Pfs25 exhibited a low α-helical content based on circular dichroisim, consistent with the structure of the same protein in an antibody complex ( Supplementary Fig. 1 ) 28 . Following Pfs25 binding to CoPoP liposomes, we assessed whether monoclonal antibodies (mAbs) recognized the correctly folded protein conformation. 4B7 has been reported to be a conformational-specific mAb 4 . Recently, two non-overlapping epitopes have been identified by functional mAbs (1269 and 1245) 28 . The 1269 mAb binds to a similar epitope as 4B7, while 1245 binds a distinct region. Following incubation with Pfs25-specific mAbs, protein G beads were used to immunoprecipitate the entire liposome-antigen complex, which was then detected by endogenous PoP or CoPoP fluorescence following detergent disruption. As shown in Fig. 1f , 4B7, 1269 and 1245 immunoprecipitated whole CoPoP liposomes bound with his-tagged Pfs25, but not PoP liposomes (which do not bind Pfs25). As both 1269 and 1245 bind to Pfs25 in a reduction-sensitive fashion, these results suggest that particleized Pfs25 maintains a correct conformation. A mAb against a human immunodeficiency virus envelope segment (2F5) and another TBV antigen, Pfs48/45 (3E12), served as negative controls.
Cryo-electron microscopy revealed that CoPoP/PHAD liposomes were small and unilamellar, with a spherical size close to 100 nm (Fig. 1g) . Following Pfs25 binding, liposome curvature changed subtly, forming more oblong structures (Fig. 1h) . Individual proteins were not visible due to their small size. Based on light scattering, the liposomes were approximately 100 nm in diameter (Supplementary Fig. 2a ). Minimal change in size or 
NAture NANotecHNology polydispersity was induced by SNAP ( Supplementary Fig. 2a,b) . SNAP did not substantially impact the CoPoP/PHAD liposome surface charge ( Supplementary Fig. 2c ), which had a negative zeta potential, consistent with other observations of liposomes containing monophosphoryl lipid A 29 . Refrigerated storage stability was assessed over nine months. Minimal change was observed in liposome size, which was close to 100 nm ( Supplementary Fig. 3a ), or polydispersity index, which remained less than 0.1 ( Supplementary Fig. 3b ). The spontaneous Pfs25 binding capacity of the liposomes remained intact throughout ( Supplementary Fig. 3c ). Four separate batches of CoPoP/PHAD liposomes exhibited similar size, polydispersity and capacity for Pfs25 binding ( Supplementary Fig. 3d-f ).
Antigen particleization induces strong antibody responses
Mice were immunized intramuscularly with 100 ng of Pfs25, mixed just before vaccination with alum, Montanide ISA 720, CoPoP liposomes or CoPoP/(3-deacyl)-(6-acyl) PHAD (3D6A) liposomes. 3D6A is a structurally similar form of PHAD used in our initial immunization studies. In all immunizations, a fixed mass ratio for PHAD:Pfs25 of 4:1 was used. No additional purification steps were taken after combining the antigen with the adjuvants. As shown in Fig. 2a , all CoPoP liposomes induced the production of immunoglobulin G (IgG) that was functional in a standard membrane-feeding assay (SMFA). Liposomes lacking cobalt produced orders-of-magnitude lower anti-Pfs25 IgG and did not induce SMFA activity (Supplementary Table 1 ). At 100 and 30 ng dosing, both CoPoP/PHAD liposomes and CoPoP liposomes induced strong IgG and full SMFA activity (Fig. 2b and Supplementary Table 2) . However, at a 10 ng dose of Pfs25, only CoPoP/PHAD liposomes induced antibody production with full SMFA activity. At 100 ng Pfs25, inclusion of PHAD resulted in higher production of IgG2a and a higher IgG2a:IgG1 ratio compared with CoPoP liposomes lacking PHAD ( Supplementary Fig. 4a,b) .
Further dose de-escalation was performed in mice. CoPoP/ PHAD liposomes that included the saponin QS21 were also examined. With this DPPC-based formulation, QS21 induced liposome aggregation, although Pfs25 binding was not impaired (Supplementary Fig. 5 ). Addition of QS21 did not enhance Pfs25 antibody production (Fig. 2c ) and appeared to decrease IgG2a production ( Supplementary Fig. 4c,d ). CoPoP/PHAD liposomes induced antibodies that were effective in the SMFA at antigen doses down to 4 ng (Supplementary Table 3 ). This corresponds to 16 ng of PHAD, which is 1,000-fold lower than what is typically used for murine immunization 29 . Safety studies were carried out using high doses of CoPoP. To ascertain whether CoPoP itself is tolerated, we formed CoPoP liposomes with 95 mol% CoPoP, along with 5% polyethylene glycol distearoylphosphoethanolamine (PEG-lipid) for colloidal stability. CoPoP liposomes were then directly injected intravenously 
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NAture NANotecHNology into mice at a dose of 100 mg kg −1 (CoPoP). This CoPoP dose was approximately 138,000 times higher than the minimum dose administered to mice that induced functional SMFA activity (4 ng Pfs25 and 16 ng CoPoP). Another group of mice was injected intramuscularly with a single dose of 20 µ g Pfs25 adjuvanted with CoPoP/ PHAD liposomes, corresponding to a 5,000-fold higher dose than the minimum functional dose. Mice exhibited normal weight gain (Fig. 2d) . A complete blood cell count ( Supplementary Fig. 6a ) and serum chemistry panel analysis ( Supplementary Fig. 6b ) two weeks following treatment revealed no statistically significant differences compared with healthy mice. No obvious differences in the liver, lungs, kidney or spleen of mice were observed with histology ( Supplementary Fig. 6c ). Thus, CoPoP liposomes appear to be well tolerated, although additional toxicity studies are required. Vitamin B12-a cobalt(iii) porphyrin-related macrocycle-has been administered intravenously to healthy human volunteers at 5 g dosing To assess whether SNAP immunization elicits transmissionblocking antibodies in rabbits, intramuscular immunization was carried out with 10 µ g of Pfs25 on days 0 and 28. When mixed with CoPoP/PHAD liposomes, but not alum, strong anti-Pfs25 IgG titres were induced by day 56, and also pre-boost on day 28 ( Fig. 2e) . The post-immune sera from the rabbits immunized with SNAP, but not alum, produced transmission-blocking activity in the SMFA ( Fig. 2f and Supplementary Table 5 ). Even at a tenfold lower antigen dose of 1 µ g Pfs25 (4 µ g PHAD), transmission-blocking antibody activity was induced in two of three rabbits immunized with SNAP.
Vaccine mechanism
Next, we sought to elucidate mechanistic insights into SNAP immunization, which is hypothesized to operate at multiple steps of immune activation (Fig. 3a) . Serum-stable antigen particleization enables intact transit of the antigen-liposome complexes to draining lymph nodes, where they are more avidly taken up by immune cells. Additional factors, including recruitment of immune cells to the draining lymph nodes and downstream activation of dendritic cells, probably contribute to the formation of germinal centres, the recruitment of T-follicular helper (Tfh) cells and, ultimately, the generation of long-lived, antigen-specific plasma cells.
To monitor antigen-adjuvant association, Pfs25 was labelled with the fluorescent dye Oyster 488, generating Pfs25-488. When Pfs25-488 was incubated with CoPoP/PHAD liposomes, but not PoP/PHAD liposomes, fluorophore proximity to the CoPoP chromophore induced fluorescence quenching. When incubated in human serum for 2 wk at 37 °C, Pf25-488 binding to CoPoP/PHAD liposomes remained intact, whereas no binding occurred with PoP/PHAD liposomes (Fig. 3b) . Following the 2 wk incubation period, fluorescence of the dye could be restored upon dissociation ( Supplementary Fig. 7a,b) . Binding was also stable in bovine serum ( Supplementary Fig. 7c ).
To investigate the innate response, 100 ng Pfs25 was mixed with CoPoP/PHAD liposomes or alum and intramuscularly administered to mice. Immune cell recruitment in draining lymph nodes was measured 48 h following injection using a flow cytometry discrimination approach ( Supplementary Fig. 8a ) 32, 33 . CoPoP/PHAD liposomes induced higher recruitment of macrophage and infiltrating monocytes compared with alum ( Fig. 3c ). Increased levels of CD11b − dendritic cells were noted in both the alum and CoPoP/ PHAD liposome groups. Cd11b
− dendritic cells play a role in cellular adaptive immune responses [34] [35] [36] . In immunized mice, splenocytes produced interferon gamma when incubated with the antigen, demonstrating the involvement of T cells ( Supplementary Fig. 9 ). Other immune cell types (eosinophils, neutrophils, CD11b low dendritic cells and myeloid dendritic cells) did not increase in draining lymph nodes. The increased levels of certain immune cells in the draining lymph nodes, by just two-to threefold, do not fully account for the drastic enhancement in antibody production induced by SNAP.
Following injection of fluorescently labelled Pfs25-488, lymphatic antigen drainage was modulated relative to alum, resulting in greater lymph node accumulation, which may have some positive impact on immunogenicity ( Supplementary Fig. 10 ). However, the enhanced lymph node biodistribution of only several fold does not account for the greater antibody response by several orders of magnitude.
Next, the uptake of the antigen-liposome complex into antigen-presenting cells (APCs) was examined in vitro using fluorescence microscopy ( Fig. 3d) . When Pfs25-488 was incubated with RAW264.7 murine macrophages, no cellular antigen uptake was observed. No antigen uptake was observed when Pfs25-488 was mixed with PoP/PHAD liposomes. However, the fluorescence of the liposomes themselves was detected, since macrophages avidly uptake liposomes 37, 38 . When Pfs25 was presented on liposomes using SNAP with CoPoP/PHAD liposomes, both antigen and liposome uptake occurred. Quantitative measurement of Pfs25 uptake confirmed this trend in both murine macrophages and murine bone-marrowderived dendritic cells (BMDCs)-another class of APCs (Fig. 3e ). In the presence of cytochalasin B (a phagocytosis inhibitor), diminished Pfs25 uptake occurred, suggesting a phagocytic uptake mechanism.
Next, we examined whether enhanced uptake of Pfs25 in APCs occurred in draining lymph nodes. As shown in Fig. 3f and Supplementary Fig. 11 , 2 d following SNAP immunization of mice, Pfs25 was taken up in all major types of APCs, including B cells (B220), macrophages (F4/80), dendritic cells (CD11c) and major histocompatibility complex II (MHC-II)-expressing cells (I-A/I-E). In contrast, when adjuvanted with alum, ISA 720 or non-particleizing PoP/PHAD liposomes, there was minimal Pfs25 uptake into most APC types. Thus, improved delivery to APCs appears to be a key mechanism in which SNAP exerts enhanced immunogenicity compared with other adjuvants.
Maturation of dendritic cells involves upregulation of surface receptors, including CD40 and CD80. When BMDCs were incubated with Pfs25 for 24 h, CD40 and CD80 production increased when the antigen was combined with CoPoP/PHAD liposomes, compared with the protein alone or liposomes lacking PHAD ( Fig. 3g and Supplementary Fig. 12 ). PHAD has been shown to stimulate BMDC activation 39 . Thus, concomitant dendritic cell activation by PHAD may provide an additional mechanism of enhanced immune response.
Germinal centre cell formation and the recruitment of Tfh cells were assessed. Germinal centre B cells were identified by gating on B220 + cells and examining CD95 Fig. 14) . One week following murine intramuscular immunization, when combined with CoPoP/PHAD liposomes, Pfs25 induced a higher number of germinal centre B cells and Tfh cells in draining lymph nodes (Fig. 3h,i) . There was no increase in these cell populations when Pfs25 was administered with alum.
efficacy of SNAP immunizationAdditional adjuvants
The durability of the antibody response for a TBV is important. A recent study using Pfs25-toxin conjugates reported antibody half-lives in the 50− 100 d range 13 . Following SNAP immunization with 100 ng Pfs25, antibody levels did not decrease to half of the day 42 levels by day 250, corresponding to an antibody half-life of greater than 250 d (Fig. 4a) . Antigen-specific, long-lived plasma cells (CD138
− ) were detected in the bone marrow of mice on day 250 ( Fig. 4b and Supplementary Fig. 15 ), confirming an immunological basis for the long-lived antibody response. Serum drawn from mice at day 250 was active in transmission blocking based on the SMFA (Fig. 4c) .
Additional adjuvants were compared with CoPoP/PHAD in a head-to-head study. Commercial adjuvants included alum, TiterMax, Adju-Phos, Quil-A, Sigma Adjuvant System, AddaVax (similar to MF59) and Freund's Adjuvant (Complete Freund's ; within the CD4 + cell population) (i) in draining lymph nodes 7 d after intramuscular immunization with 100 ng Pfs25. In e and g, values show means ± s.d. for n = 3 biologically independent experiments. In h and i, lines show means for n = 5 mice per group. Asterisks show significance as determined by unpaired, two-tailed Student's t-test: *P < 0.05; **P < 0.01; ***P < 0.005. 
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Adjuvant (CFA)/Incomplete Freund's Adjuvant (IFA)). A 100 nm formulation containing dioleoylphosphatidylcholine, PHAD and QS21 was prepared with a similar composition to AS01 (ref.
40
). Only the CoPoP/PHAD adjuvant induced high levels of Pfs25 antibodies with 100 ng Pfs25, presumably owing to the importance of antigen particleization (Fig. 5a ). Despite the potent response, CoPoP/PHAD liposomes with Pfs25 produced the least amount of local reactogenicity of all the adjuvants assessed when injected intradermally in the footpad, as assessed by swelling (Fig. 5b) .
The effect of Pfs25 density on the liposomes was assessed with a low dose (10 ng) of Pfs25. Density was compared under standard conditions (estimated at 121 proteins per liposome based on protein binding, liposome diameter and geometrical considerations 41 ) and a reduced density of just 5% of that amount (6 proteins per liposome). The higher-density antigen resulted in more production of anti-Pfs25 IgG by approximately one order of magnitude ( Supplementary Fig. 16a ). However, post-immune sera for both high and low antigen density fully inhibited parasite development in the SMFA (Supplementary Fig. 16b ), implying that a sufficient level of antibodies was induced to saturate the assay. We conclude that the SNAP approach is effective at generating functional antibodies over a wide range of antigen densities, even at low antigen injected doses.
The use of CoPoP/PHAD liposomes that are combined with separately produced antigen at the time of immunization may have advantages in modular research and early-phase clinical trials, since only a single batch of sterile liposomes would be required. However, it could eventually be beneficial to develop a single vial formulation without the requirement of a mixing step. We assessed whether Pfs25, once bound to CoPoP/PHAD liposomes, would be a stable formulation. As shown in Supplementary Fig. 17a-c, Pfs25 binding remained intact over one month, as did liposome size and polydispersity. No free protein was detected by native polyacrylamide gel electrophoresis (PAGE) following six weeks of storage ( Supplementary Fig. 17d ). When electrophoresis was performed under reducing and denaturing conditions (which triggers release of the his-tagged protein), no Pfs25 degradation was observed ( Supplementary Fig. 17e ). Pfs25 that was pre-incubated for multiple weeks at 4 °C before vaccination (100 ng for both the prime and boost) induced no difference in IgG generation ( Supplementary  Fig. 17f) . Thus, the SNAP approach could be applicable to both bedside mixing and generation of batches of particleized antigens.
Antigen multiplexing
The multistage life cycle of Plasmodium species, in which different proteins are exposed on the parasite surface at different stages, may be a contributing factor to the difficulty of creating an effective malaria vaccine. Multistage, multi-antigen malaria vaccines are considered to be a promising avenue of research 42 . However, the process of developing and biochemically characterizing multistage, multi-antigen vaccines is challenging. CoPoP/PHAD liposomes could facilitate this process since well-defined his-tagged antigens can easily be mixed with the liposomes to undergo SNAP. The antigen composition would be easily adjustable and no chemical conjugation or purification steps are required.
We examined a panel of his-tagged P. falciparum antigens expressed at different stages of the parasite life cycle. The concept is that these antigens could all be combined into a single particle by simple mixing before immunization (Fig. 6a) The binding of each his-tagged protein antigen (Pfg27, Pfs25, Pfs230 and AMA-1), as well as the multiplexed combination, was assessed using native PAGE (Fig. 6b ). When incubated with CoPoP/ PHAD liposomes, the proteins bound efficaciously, and no free protein bands were seen on the gel. The proteins had appropriate sizes and charges to enable the multiplexed antigen binding to also be confirmed with individually resolved antigens. Microcentrifugal filtration confirmed the binding of each antigen to CoPoP/PHAD liposomes, but not identical liposomes lacking cobalt (Fig. 6c) . Following antigen binding, the size of the multiplexed liposomes remained around 100 nm (Fig. 6d) , and the polydispersity was less than 0.3 ( Supplementary Fig. 18 ). Thus, CoPoP liposomes are amenable for SNAP of multiple antigens simultaneously.
Mice were immunized with 100 ng of each antigen, either individually or multiplexed. A fixed mass ratio of PHAD:antigens of 4:1 was used in all cases. When immunized with individual antigens, specific IgG was induced for all antigens without cross-reactivity (Fig. 6e) . The multiplexed SNAP vaccine resulted in high IgG production against all the antigens. Alum was ineffective for multiplexing antigens, with significant IgG levels only detected for one (out of five) antigens: Pfs230. Analysis of the SNAP multiplexed response revealed a slight decrease in the IgG levels against Pfs25 and Pfs230 compared with their single antigen vaccination counterparts. In contrast, there was a substantial increase in the anti-CSP IgG titre of the multiplexed vaccine. A duplex vaccine of Pfs25 combined with NANP was sufficient to generate increased levels of anti-CSP IgG (Supplementary Fig. 19 ).
Next, we investigated whether multiplexed SNAP immunization induced antibodies that recognize native P. falciparum proteins. Different life stages of the parasite, including sporozoites, ookinetes, gametocytes and schizonts, were subjected to an immunofluorescence assay. Post-immune sera from mice immunized with individual his-tagged antigens exhibited expected patterns of reactivity for the individual life stages of parasites ( Fig. 6f and Supplementary  Fig. 20 ). The post-immune sera from mice SNAP immunized with multivalent antigens recognized all expected life stages of the parasite. Multiplexed antigens adjuvanted with alum did not induce effective antibodies, with the only response being observed with Pfs230. The mechanism by which SNAP immunization exerts a balanced immune response requires further characterization, but may relate to the low antigen dose used, or improved and balanced antigen uptake in APCs.
Conclusion
Recombinant his-tagged proteins spontaneously bind to liposomes containing CoPoP. This enables the rapid, gentle and uniformly oriented particleization of well-characterized, purified his-tagged antigens. The SNAP approach safely induced durable antibody responses orders of magnitude greater than other adjuvants. In mice, functional antibodies were induced with nanograms of Pfs25, showing potential for antigen-sparing practices. SNAP immunization was well suited for multiplexed immunization with at least five his-tagged antigens-an approach that may be of interest for developing recombinant vaccines that target different life stages of the malaria parasite.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41565-018-0271-3. Materials. His-tagged Pfs25 was produced in a baculovirus system as previously described 10 . His-tagged plant-derived Pfs25 for enzyme-linked immunosorbent assay (ELISA) coating was produced in Nicotiana benthamiana as previously reported 45 . His-tagged Pfs230 was produced in a baculovirus system as previously reported 46 . His-tagged AMA-1 was produced in Escherichia coli as previously reported 47 . His-tagged Pfg27 (MRA-1274) was obtained from BEI Resources, and a (NANP) 6 -(His) 7 peptide was synthesized by GenScript. CSP for ELISA was produced in E. coli as previously reported 48 . CoPoP was produced as previously described 23 . The following adjuvants were obtained: AddaVax (InvivoGen; catalogue number: vac-adx-10), Adju-Phos (InvivoGen; catalogue number: vac-phos-250), Quil-A (InvivoGen; catalogue number: vac-quil), TiterMax Gold Adjuvant (Sigma; catalogue number: T-2684), Sigma Adjuvant System (Sigma; catalogue number: S-6322), Imject IFA for the prime and CFA for the boost (Fisher; catalogue numbers: 77145 and 77140, respectively), Montanide ISA 720 (SEPPIC) and Alhydrogel 2% aluminium gel (Accurate Chemical And Scientific Corporation; catalogue number: A1090BS). The following lipids were used: DPPC (Corden; catalogue number: LP-R4-057), Ni-NTA lipid dioleoylglycero-Ni-NTA (Avanti; catalogue number: 790404P), 1,2-dioleoyl-sn-glycero-3-phosphocholine (Avanti; catalogue number: 850375), cholesterol (PhytoChol; Wilshire Technologies), PEGlipid (DSPE-PEG2K; Corden; catalogue number: LP-R4-039), synthetic PHAD (Avanti; catalogue number: 699800P) and 3D6A (Avanti; catalogue number: 699855P). QS21 was obtained from Desert King. Granulocyte-macrophage colonystimulating factor (GM-CSF) was obtained from Shenandoah Biotechnology (catalogue number: 200-15-AF). Cytochalasin B was obtained from Acros (catalogue number: 228090010).
Cell studies. RAW264.7 murine macrophage cells were obtained from the American Type Culture Collection and cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.
BMDCs were derived from bone marrow cells obtained from CD-1 mice. Bone marrow was collected from the femurs and tibia of mice. The concentration of cells was seeded at 10 7 cells ml −1 and cultured in a 10 cm petri dish in Roswell Park Memorial Institute 1640 culture medium with 10% FBS and 20 ng recombinant GM-CSF on day 0. On day 3, an additional 10 ml medium containing GM-CSF was added to the petri dish to give a final volume of medium of 20 ml. On day 6, non-adherent cells were collected and cultured in a 24-well plate at 5 × 10 5 cells ml
in Roswell Park Memorial Institute culture medium containing 10% FBS and 1% penicillin/streptomycin, then incubated for 24 h with CoPoP/PHAD, CoPoP and phosphate buffered saline (PBS) mixed at 1 µ g ml −1 Pfs25, with a fixed CoPoP:Pfs25 mass ratio of 4:1. Cells were washed with PBS containing 0.1% bovine serum albumin (BSA) three times and stained with antibodies against CD11c, CD40, CD80 and MHC-II for 1 h on ice before flow cytometry.
For the in vitro uptake studies, RAW264.7 cells and BMDCs (5 × 10 5 well −1 ) were cultured in a 24-well plate overnight to reach 70-80% confluence. Cells were then either: (1) treated with various types of liposomes with 1 µ g ml −1 of Pfs25-488; or (2) pre-incubated with cytochalasin B (10 µ g ml
) for 1 h before the uptake study. For quantification, after incubation for 4 h, the cells were harvested, washed with PBS three times and treated with lysis buffer (1% Triton X-100 and 0.1% sodium dodecyl sulfate in PBS). The fluorescence signal was measured and the cellular Pfs25 uptake was calculated by first preparing a Pfs25-488 standard curve and calculating the concentration based on the standard curve.
Liposome preparation. Liposomes were prepared by ethanol injection and nitrogen-pressurized lipid extrusion in PBS. This procedure was carried out at 60 °C followed by dialysis to remove the ethanol. For liposomes containing QS21, the QS21 (1 mg ml
) was added to the liposomes after formation at a mass ratio equal to PHAD. The final liposome concentration was adjusted to 320 μ g ml
PHAD and the solution was passed through a 0.2 μ m sterile filter and stored at 4 °C. Liposome sizes and polydispersity indices were determined by dynamic light scattering with a NanoBrook 90Plus PALS instrument after 200-fold dilution in PBS. The standard CoPoP/PHAD liposome formulation had a mass ratio of DPPC:cholesterol:PHAD:CoPoP of 4:2:1:1. Other formulations are detailed in the Supplementary Information. SNAP characterization. Protein binding with Pfs25 or lysozyme (VWR; catalogue number: 97062-138) was carried out by incubating protein and liposomes with a 1:4 mass ratio of protein:PHAD, unless otherwise stated. Following incubation, the sample was subjected to microcentrifugal filtration (Pall; catalogue number: 29300), and protein in filtrate was assessed by Micro BCA (Thermo Fisher Scientific; catalogue number: 23235). For gel electrophoresis, loading dye was added to liposome samples, loaded into PAGE gels (Lonza; catalogue number: 8522) and subjected to electrophoresis and staining. Cryogenic transmission electron microscopy was carried out as described in the Supplementary Information. Samples for immunization were prepared in the same way, but diluted in PBS to achieve the desired antigen dosing, with the antigen:PHAD mass ratio remaining constant (1:4) . SNAP multiplexing. Multiplexing was carried out by mixing CoPoP/PHAD liposomes with five different his-tagged malaria antigens (Pfs25, Pfs230, Pfg27, AMA-1 and NANP) for 3 h at room temperature in the same way as Pfs25. A constant mass ratio of antigen:PHAD of 1:4 was maintained in all cases.
Murine immunization and serum analysis. CD-1 mice (8 wk old, female) received intramuscular injections on days 0 and 21 containing the indicated antigen doses combined with the indicated adjuvants. Serum was collected on day 42 unless otherwise indicated and sent to the Laboratory of Malaria and Vector Research at the National Institute of Allergy and Infectious Diseases for anti-Pfs25 ELISA 49 and SMFA 50, 51 analysis, which were carried out as previously described. Supplementary  Tables 1-5 report the raw SMFA data.
Rabbit immunization. New Zealand white rabbits (10-12 wk old, female) received intramuscular injections on days 0 and 28 of 1 or 10 µ g Pfs25 adjuvanted with CoPoP/PHAD (4 or 40 µ g PHAD) liposomes or 10 µ g Pfs25 with alum. Serum samples were collected on days 0, 28 and 56. Serum was sent to the National Institute of Allergy and Infectious Diseases for ELISA and SMFA analysis.
Flow cytometry.
Flow cytometry studies were carried out using a BD LSRFortessa X-20 flow cytometer. FlowJo (version 10) software was used for data analysis.
For the draining lymph node studies of Pfs25 uptake in immune cells, mice were intramuscularly immunized with 1 µ g of Pfs25-488 conjugate. Then, 2 d after injection, they were killed and inguinal lymph nodes were collected. Cells were extracted and fixed with 4% paraformaldehyde at room temperature for 15 min, then washed three times with 3 ml PBS under centrifugation at 500 r.c.f. for 5 min. Some 5 × 10 5 cells per tube were stained for 30 min at room temperature with murine antibodies against I-A/I-E, B220, CD11c or F4/80 (all from BioLegend).
To stain marrow cells, on day 250, mice were killed and bone marrow was collected. Marrow cells were counted, fixed with 4% paraformaldehyde at room temperature for 15 min in the dark, washed three times with PBS and frozen in 10% dimethyl sulfoxide. Cells were stained with anti-CD138 and anti-B220 antibodies (BioLegend) for 30 min at room temperature in the dark, followed by three PBS washes. Cells were permeabilized with 0.1% Triton X-100 and stained with Pfs25-488, followed by additional washing before flow cytometry.
For the germinal centre cells and Tfh cell populations, mice received 100 ng Pfs25 adjuvanted with CoPoP/PHAD or alum. Then, 14 d after immunization, the mice were killed and the inguinal lymph nodes were collected. Cells extracted from the lymph nodes were fixed with 4% paraformaldehyde for 15 min at room temperature, and washed three times with 3 ml PBS under centrifugation at 500 r.c.f. for 5 min. Some 5 × 10 5 cells per tube were than stained for 1 h on ice with antibodies against B220, CD95, GL7, CD4, CXCR5 or PD-1 before flow cytometry.
For lymph node cell recruitment, mice were injected intramuscularly with CoPoP/PHAD liposomes or alum with 100 ng of Pfs25. Then, 48 h after injection, the mice were killed and lymph nodes were collected for cell extraction. Cells were fixed with 4% paraformaldehyde for 15 min at room temperature and washed with PBS three times. Cells were stained with a combination of antibodies against Ly6C, CD11b, Ly6G, CD11c, CD3, I-A/I-E and F4/80 for 1 h on ice. Cells were first gated with CD11c and CD11b ( Supplementary Fig. 8a ). Then, immune cells were identified based on surface markers in CD11c high and CD11b Acute toxicity studies. CD-1 mice (8 weeks old, female) were treated with an intramuscular injection of CoPoP/PHAD/Pfs25 prepared in the usual way with 20 µ g Pfs25, or with intravenous injection of CoPoP/PEG liposomes (95:5 molar ratio of CoPoP:PEG) at 100 mg kg −1 CoPoP. Two weeks later, blood and serum were collected and subjected to standard complete blood cell count and serum panels (IDEXX; catalogue number: 98-20590-00). Organs, including the kidney, lung, liver and spleen, were fixed in formalin for 24 h, then transferred to 70% ethanol and subjected to haematoxylin and eosin staining. Briefly, slides were de-waxed through xylenes and graded alcohols; transferred to water for 3 min, haematoxylin for 3 min, water for 3 min, 1% acid alcohol for 1 min, water for 3 min, 0.2% ammonium hydroxide for 3 min, water for 4 min, 95% ethanol for 3 min and eosin for 30 s; and then dehydrated through graded alcohols, cleared, mounted and coverslipped with xylene mount before imaging.
Indirect immunofluorescence assay. P. falciparum schizonts, gametocytes, ookinetes and sporozoites were obtained and fixed on slides as described in the Supplementary Methods. Slides were blocked with 5% BSA in PBS containing 0.1% Tween-20 for 30 min at 37 °C. Serum collected from mice immunized with individual or multiplexed antigens with SNAP or alum was diluted 1:100 and incubated in 5% BSA in PBS with the fixed slides at 37 °C for 1 h, followed by three washes with PBS in a humidity chamber, each time for 5 min. Fluorescein isothiocyanate-conjugated goat anti-mouse IgG (1:1000) was then incubated with the slides for 30 min at 37 °C, followed by three washes with PBS, each time for 5 min. 
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data analysis
Excel and GraphPad Prism6 were used for data analysis and plotting. FlowJo was used for flow cytometry analysis. Image Lab software were used for Native PAGE and SDS PAGE. Coreldraw was used to arrange figures.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Authentication No authentication was carried out. Cell morphology and adhesion was consistent with expectations.
Mycoplasma contamination
Cell lines were not tested for mycoplasma.
Commonly misidentified lines (See ICLAC register) No commonly misidentified cell lines were used in this study.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals 8-week-old female CD-1 mice, 10-12 week old female New Zealand white rabbits.
Wild animals
This study did not involved wild animals.
Field-collected samples
This study did not involved field-collected samples.
Flow Cytometry Plots
Confirm that:
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The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
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Methodology
Sample preparation
For immune cell recruitment in lymph nodes, (Fig 3C, Fig S8) Mice were injected intramuscularly with CoPoP/PHAD liposomes or Alum with 100 ng of Pfs25. 48 hr after injection, mice were sacrificed and lymph nodes were collected for cell extraction. Cells were fixed with 4 % PFA for 15 min at room temperature, and washed with PBS for 3 times. Cells were stained with combination antibodies against Ly6C, CD11b, Ly6G, CD11c, CD3, I-A/I-E and F4/80, for 1 hr on ice. For antigen uptake into draining lymph node immune cells (Fig 3F, Fig S11) Cells collected from the lymph node were from mice injected with Pfs25 oyster-488, after 2 days of injection the mice were sacrificed and lymph node were collected and pass through cell strainer. The cells were later fix with 4% PFA and stained with fluorescence-labeled antibodies. Cells (5X105 cells per tube) were aliquot into each tube for staining with specific antibodies, including I-A/I-E (MHCII), PE F4/80, APC CD11c, APC CD45R/B220. The cells were stained for 30 min at room temperature, and followed by 3 time washing with PBS. For GC B cells staining (Fig 3H, Fig S13) and Tfh cells (Fig 3I , Fig S14) For GC cells and Tfh cell populations, mice received 1 μg Pfs25 adjuvanted with CoPoP/PHAD or Alum. 14 days after immunization, mice were sacrificed and the inguinal LN were collected. Cells extracted from the lymph nodes were fixed with 4% paraformaldehyde for 15 min at room temperature, washed three times with 3 mL PBS with centrifugation at 500 rcf for 5 min. 5×105 cells per tube were than stained for 1 hr on ice with antibodies against B220, CD95, GL7. CD4, CXCR5 or PD-1 prior to flow cytometry. For assessing long-lived plasma cells (Fig 4B, Fig S15) Bone marrow cells collected from mice, the cells were collected and pass through cell strainer. Red blood cells were lysis using commercial lysis buffer. Later the cells were fix with 4% PFA and stained with fluorescence-labeled antibodies, followed by intracellular staining with intracellular marker. Cell (5X105 cells per tube) were aliquot into each tube for staining with specific antibodies, including APC CD45R/B220 and PE CD138. The cells were stained for 30 min at room temperature, and followed by 3 time washing with PBS. . Cells were later permeabilized with 0.1 % Triton X-100 and stained with Pfs25-oyster488, followed by 3 times washing with 0.1% Triron X-100, and 3 time washing with PBS. For BMDC activation (Fig 3G, Fig S12) After cells incubated for 24 hr with CoPoP/PHAD, CoPoP, and PBS mixed at 1 μg/mL Pfs25, with a fixed 4:1 mass ratio of CoPoP to Pfs25. Cells were washed with PBS containing 0.1% BSA for 3 times, and stained with antibodies against CD11c, CD40, CD80 and MHC-II for 1 hr on ice prior to flow cytometry.
Instrument
The instrument we used for data collection is the BD LSRFortessa X-20.
Software
The software we used for flow analysis is FlowJo V10.
Cell population abundance For the lymph node, there are 7.5% of B220 positive cells, 4. nature research | reporting summary
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Gating strategy I. For immune cell recruitment in lymph nodes, (Fig 3C, Fig S8) Cells were first gated with CD11c and CD11b (Fig S8A) . Then immune cells were identified based on surface marker in CD11chigh and CD11blow, neutrophils (Ly6Ghigh) (Fig S8D) , eosinophils (Ly6Gint, F4/80int, SSC) (Fig S8E) , monocytes (Ly6C high) (Fig S8C) and macrophage (F4/80 high) (Fig S8B) . Three types of DC cells were gated (Fig S8F) , for myeloid DC, we first gate Cd11chigh and CD11bhigh, then gated MHC-II positive cells. II. For antigen uptake into draining lymph node immune cells (Fig 3F, , Fig S11) The cells were first gated with SSC/FSC, then compared to the unstained cells, the population of cells were gated with B220 positive, I-A/I-E positive, CD 11c positive and F4/80 positive. Later on, by comparing the groups of Pfs25-oyster 488 injected mice to the group of untreated mice, the Pfs25 positive cells were gated. III. For GC B cells staining (Fig 3H, Fig S13) and Tfh cells (Fig 3I , Fig S14) GC B cells: The cells were gated with SSC/FSC, then gated with B220 + cells, and finally gated with GL7+CD95+ cells. Tfh cells: The cells were gated with SSC/FSC, then gated with CD4 + cells, and finally gated with CXCR5+PD-1+ cells. For assessing long-lived plasma cells (Fig 4B, Fig S15) The cells were first gated with SSC/FSC,then compared to the unstained cells, the population of cells were gated with CD138 positive and B220 negative. Pfs25 positive cells were gated by comparing control mice to immunized mice. IV. For BMDC activation (Fig 3G, Fig S12) The cells were first gate with SSC/FSC, then gated with CD40, CD80, MHCII or CD11c positive cells.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
